Brand Name(s): Epivir; Epivir-HBV
CAS nº: 134678-17-4
(la mih vue deen)
About Lamivudine
This new site is dedicated exclusively to lamivudine.
It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about lamivudine on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.
This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total lamivudine experience!
Why is this medication prescribed?
Lamivudine is an antiviral medication. It is in a group of human immunodeficiency virus (HIV) medicines called reverse transcriptase inhibitors. Lamivudine helps keep the HIV virus from reproducing in the body.
The Epivir® brand of lamivudine is used to treat HIV and hepatitis B viruses, which cause the acquired immunodeficiency syndrome (AIDS). On the other hand, the Epivir-HBV® brand of lamivudine is used to treat chronic hepatitis B.
Lamivudine is not, however, a cure for HIV or AIDS.
Latest News
HIV/AIDS Update - Epivir Tablets for Pediatric Dosing
FDA has approved a new formulation of Epivir (lamivudine) designed to facilitate dosing in...
[more]Abacavir/Lamivudine Noninferior to Tenofovir/Emtricitabine as Backbone to Lopinavir/Ritonavir HIV Therapy: Presented at CROI
Doctors reported that the combination of the nucleoside reverse transcriptase inhibitors...
[more]What is the more suitable for early detection of low abundant lamivudine-resistant mutants?
Lamivudine is an effective antiviral agent for treatment of patients with chronic hepatitis B and...
[more]WHO Adds Three Ranbaxy Antiretrovirals to Prequalification List
Indian pharmaceutical company Ranbaxy Laboratories on Monday announced that the World Health...
[more]FDA Approves New Treatment for Chronic Hepatitis B in Adults
The Food and Drug Administration (FDA) today approved Tyzeka (telbivudine) for the treatment of...
[more]